Novo Nordisk A/S (NYSE:NVO) Stock Holdings Lifted by Capital Research Global Investors

Capital Research Global Investors lifted its stake in shares of Novo Nordisk A/S (NYSE:NVOFree Report) by 1.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,052 shares of the company’s stock after acquiring an additional 407 shares during the quarter. Capital Research Global Investors’ holdings in Novo Nordisk A/S were worth $3,523,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in NVO. Pacific Center for Financial Services increased its holdings in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. CNB Bank acquired a new position in shares of Novo Nordisk A/S during the 4th quarter valued at about $26,000. Tyler Stone Wealth Management grew its holdings in Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after buying an additional 146 shares during the last quarter. West Paces Advisors Inc. grew its holdings in Novo Nordisk A/S by 100.0% in the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock valued at $27,000 after buying an additional 150 shares during the last quarter. Finally, Valued Wealth Advisors LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $142.87 on Friday. The stock has a 50 day moving average of $129.73 and a two-hundred day moving average of $119.00. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $143.73. The company has a market capitalization of $641.13 billion, a P/E ratio of 49.27, a P/E/G ratio of 1.47 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The company had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. As a group, equities analysts expect that Novo Nordisk A/S will post 3.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on NVO shares. BMO Capital Markets started coverage on Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, The Goldman Sachs Group started coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.33.

Read Our Latest Stock Analysis on NVO

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Stories

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.